The bacterial infection known as melioidosis occurs sporadically throughout its endemic zone and only rarely manifests in case clusters or outbreaks. When these occur, the unusual concentration of cases presents an opportunity to advance understanding of the human, bacterial and environmental factors that result in disease. We consider how a series of expeditionary investigations have shaped our laboratory response to global melioidosis events over a period of two decades, and have enabled development of a bioreconnaissance concept for emerging infectious diseases.
On conclusion of those environmental surveillance activities we ran a targeted study of major environmental disturbance on a mine site in the East Kimberley, where we were able to detect B. pseudomallei in restored land close to mine tailings [6] . Sero-surveillance results from that study found evidence for B. pseudomallei exposure while on leave, but not during periods of work on the site. Although the mine site study was the first to use deployable PCR assays on site during field work, including a micro-fluidic capillary electrophoresis analyser, a conventional PCR thermal cycler, a high speed centrifuge and dry block heater to a remote location. Transport of this bulky equipment was logistically complex (Figure 1) . At that time, clinical microbiology lacked portable instruments for real time PCR assays, necessitating use of compact electrophoresis for analysis of amplified products of conventional PCR, following nucleic acid extraction from soil samples. Nevertheless, this work resulted in detection of B. pseudomallei -positive specimens by PCR while still on site allowing the positive sites to be revisited for intensive sampling during the same trip. The PCR -positive results were subsequently confirmed by culture in the public health laboratory, and linked to the West Kimberley outbreak strain of B. pseudomallei originally isolated eight years previously.
Overseas expeditions
A small cluster of melioidosis cases occurred in a single farming family in rural, Northeastern Brazil [7] . Initially thought to be a variant of plague, an astute pathologist considered melioidosis and found the microbiological support to identify B. pseudomallei. After an initial investigation had quickly ruled out a more sinister explanation, we were called to advise on the wider aspects of environmental investigation and risk management. Initially, this involved establishing a melioidosis investigation team under the auspices of the Ceará State Health Secretariat, with support from an infectious diseases hospital and the Federal University of Ceará. The first field trip preceded the development of WA field investigation capability and was therefore not PCR assay-enabled. Our logistic solution was shipment of in-house PCR assay reagents to NE Brazil. This proved to be logistically challenging due to a combination of cold chain sustainment and import restrictions on positive control material. Our first attempt to transfer a B.pseudomallei confirmatory assay as a reagents and method package was unsuccessful. Subsequent attempts were increasingly successful, leading to the Ceará group establishing self-sufficient laboratory confirmation of culture-positive melioidosis [8, 9] , standard laboratory methods [10] , public health guidelines [11] , and recognition of the emergence of sporadic melioidosis in the Americas [12] .
Recognition of undisclosed endemic B. pseudomallei infection in Sri Lanka
Building on the Brazil partnership we developed a molecular methods training workshop during that series of visits that have since been used to train clinical and research laboratory staff in Malaysia and Sri Lanka [13] . These regional international collaborations have now been under way for over a decade, and in the case of Sri Lanka became the foundation of a national melioidosis surveillance programme with profound implications for early diagnosis, treatment and prevention of melioidosis [14, 15] . Most notably, nationwide melioidosis surveillance has exposed a relationship between clinico-pathological disease phenotype and B. pseudomallei genotype (MLST). Through successive refinement in a series of domestic tests and deployments to Sri Lanka, the portable molecular diagnostic laboratory (now termed Lab-In-A-Box or LIAB) replaced bulky conventional PCR equipment with a single real-time thermal cycler and magnetic particle extraction (to eliminate the need for high speed centrifugation). This more compact equipment fitted in a simpler but still bulky shipment (Figure 2) . Maintenance of cold-chain continued to be a problem with PCR reagents that had limited lifespan during transit into location and subsequent field use. Most recently, very compact real-time PCR systems with solid state light sources have reduced the LIAB system to a single consumer grade suitcase with internal foam padding, or even carry-on baggage (Figures 3 and 4) . [16] . Removal of the contaminated bottle coincided with a cessation of case detections. There have been no further cases in the following four years and no cases of late onset septicaemia or relapsing soft tissue melioidosis. The long interval between the index case and the main case cluster has still not been explained, but did prepare the state public health laboratory for subsequent events because the MLST genotype was already on record when the second case occurred. Also notable was the use of previously validated MALDI-TOF mass spectroscopy [17] to rapidly identify suspect isolates from wound swabs which was possible before they gained their typical wrinkled colony appearance. Though no PCR assay capability was deployed on this occasion due to the proximity of the affected neighbourhood, the rapid laboratory response combined with willingness to task staff to support the Disease Control and lead the environmental investigation contributed to swift interruption of the outbreak. The option to deploy PCR assay capability in order to refine targeting of sample collection was available to us, had the outbreak continued unchecked. Melioidosis usually occurs as a sporadic infection of remote and rural populations. Outbreaks are rare and provide an opportunity to learn more about its biology and particularly its ecology. Our involvement in a series of melioidosis case clusters spanning two decades illustrates the additional insights from field investigations. Case clusters provided us repeated opportunities to learn lessons, some of which have had enduring benefits for the affected communities, through strengthening disease control measures. The development of compact real-time PCR thermal cyclers has enabled the necessary components of a basic molecular diagnostic laboratory to pack into a single suitcase.
Maintaining cold chain for reagents continues to present challenges but advances in stabilising PCR mastermix by lyophilisation presents an opportunity for a commercially-produced PCR assay for B.
pseudomallei that could be run on site in any location to confirm culture, directly detect in clinical specimens, or to screen soil and water samples for detectable nucleic acid. There is still much to learn by closing in on the source of a melioidosis case cluster, using new molecular investigational methods, and rapidly escalating support for a targeted response. Continual fine tuning of this cooperative emerging disease response has improved melioidosis diagnosis, treatment and prevention. Nature may be full of surprises, but as experience has demonstrated, fortune favours the bioreconnaissanceenabled laboratory.
